Institut Claudius Regaud

Recent papers from Institut Claudius Regaud

1. A Precise Activity System for Pharmacogenetics Based on Estimation of CYP2D6 A llelic Percentage Activity from the International CEPAM DatabaseClinical Pharmacology & Therapeutics · 2026
2. Prognostic Factors in Patients with Initial Low- and Intermediate-Risk Papillary Thyroid Carcinoma Who Undergo Revision Surgery Including the Central Neck CompartmentThyroid · 2026
3. The role of information and consent forms in patients’ decision-making regarding participation in oncology clinical trialsTrials · 2026
4. Exploring liverSUVmax% as a practical alternative to ΔSUVmax for interim PET/CT assessment in DLBCL: a validation cohort study and a single-centre retrospective exploratory analysisFrontiers in Medicine · 2026
5. Descriptive Analysis of Epidemiology, Demographic Characteristics, and Survival of Dedifferentiated Liposarcoma in FranceInternational Journal of Cancer · 2026
6. A multiscale pharmacokinetic-Boolean modelling framework for ibrutinib resistance in a Chronic Lymphocytic Leukaemia case study2026
7. Hormone Receptor–Positive HER2-Negative Oligometastatic Breast Cancer: prognostic stratification and pattern of progressionThe Oncologist · 2026
8. When extended metabolites profiling helps the prediction of local relapse in glioblastoma: a retrospective study using MRI and MRSIBritish Journal of Radiology · 2026
9. Radiopharmaceutical Therapy with [ 177 Lu]Lu-DOTATATE in Refractory Meningiomas: Results from the French Multicenter MELUTE CohortJournal of Nuclear Medicine · 2026
10. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trialThe Lancet · 2025
11. Value of Dual-Time-Point [ 18 F]Fluorocholine PET/CT for Challenging Preoperative Parathyroid ImagingJournal of Nuclear Medicine · 2026
12. A cytidine deaminase biodegrader sensitises multiple cancer types to deoxycytidine analogue-based chemotherapiesNature Communications · 2026
13. Tools for providing information to patients about high-tech medical resources for treatment of cancerActa Oncologica · 2026
14. Efficacy and safety of pembrolizumab–lenvatinib in metastatic endometrial cancer: results from the French multicenter early access programESMO Open · 2026
15. Explaining educational differences in return to work after early breast cancer: a mediation analysis.2026
16. Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in FranceThe Breast · 2026
17. Incorporating sliding and local rigidity constraints in neural-based image registrationScientific Reports · 2026
18. Mapping population-based cancer registries in Europe: coverage, data availability, and capacity for real-world data generationESMO Real World Data and Digital Oncology · 2026
19. Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancerScience Advances · 2026
20. The Role of Artificial Intelligence in Optimizing Diagnosis in Prostate Cancer—A Narrative ReviewJournal of Clinical Medicine · 2026